Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has granted a new patent to Hemispherx Biopharma to use Ampligen as an influenza virus vaccine adjuvant for protection against pandemic avian influenza.
Subscribe to our email newsletter
The patent covers the method of using intranasal administration of Ampligen with a seasonal influenza vaccine to boost immune response against a H5N1 avian influenza infection compared to the administration of seasonal influenza vaccine alone.
The aim of the approach reported in new patent of Hemispherx is to generate protective mucosal immunity against newly emerging and pathogenic forms of H5N1 avian influenza viruses.